MediFind
Condition

Opsoclonus-Myoclonus Syndrome

Symptoms, Doctors, Treatments, Research & More

Latest Research

Latest Advance
Study
  • Condition: Paraneoplastic Opsoclonus-Myoclonus Syndrome and Neuroblastoma
  • Journal: Pediatric blood & cancer
  • Treatment Used: Rituximab
  • Number of Patients: 14
  • Published —
This study tested the safety and efficacy of using rituximab to treat patients with paraneoplastic opsoclonus-myoclonus syndrome and neuroblastoma.
Latest Advance
Study
  • Condition: Infection-Associated Opsoclonus in Children in India
  • Journal: Journal of child neurology
  • Treatment Used: Steroids
  • Number of Patients: 15
  • Published —
This case series describes children in India who were diagnosed with infection-associated opsoclonus (rapid, uncontrolled eye movement) treated with steroids.
Latest Advance
Study
  • Condition: Opsoclonus Myoclonus Syndrome Secondary to Abdominal Neuroblastoma
  • Journal: Archivos argentinos de pediatria
  • Treatment Used: Tumor Resection and Treatment with Corticosteroids, Immunoglobulin, and Rituximab
  • Number of Patients: 1
  • Published —
This case report discusses a 2-year-old male with diagnosis of opsoclonus-myoclonus syndrome secondary to a left adrenal neuroblastoma.
Latest Advance
Study
  • Condition: Opsoclonus-Myoclonus Syndrome
  • Journal: Pediatric neurology
  • Treatment Used: Combination Corticotropin, Immunoglobulin, and Reduced-Dose Rituximab
  • Number of Patients: 32
  • Published —
This study tested the safety and efficacy of using a reduced dose of rituximab in a corticotropin, immunoglobulin, and rituximab combination to treat children with opsoclonus-myoclonus syndrome.
Latest Advance
Study
  • Condition: Neuroinflammation with Opsoclonus-Myoclonus Syndrome (OMS)
  • Journal: European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
  • Treatment Used: Cyclophosphamide, ACTH, and IVIG Combination Therapy
  • Number of Patients: 18
  • Published —
This study tested the safety and efficacy of using a combination cyclophosphamide, ACTH, and IVIG therapy to treat patients with neuroinflammation from OMS.